Sernova Biotherapeutics Inc · TSX:SVA

Sernova Biotherapeutics — Sernova — BIOInvestor Forum 2020

26 slides from Sernova Biotherapeutics's conference presentation, October 2020

  1. Slide 1: The Path To A Regenerative Medicine Cure

    Slide 1: The Path To A Regenerative Medicine Cure

    SEOVF TRADED ON The Path To A Regenerative Medicine Cure BIOInvestor Forum October 13 – 15 , 2020 th th

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward- looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expect

  3. Slide 3: Sernova: Innovator & Leader

    Slide 3: Sernova: Innovator & Leader

    Sernova: Innovator & Leader Publicly traded, clinical-stage RM therapeutics solution innovator & leader:  Cell therapy therapeutics solution platform treating chronic diseases & enhancing daily QOL  Integrated RM therapeutic solution (Cell Pouch™ + therapeutic cells or tissue + immune-protection)

  4. Slide 4: Sernova's Platform Approach

    Slide 4: Sernova's Platform Approach

    Sernova’s Platform Approach Integrated RM Therapeutic Solution for 28% 40% Treatment of Chronic Diseases 32% Cell Pouch Therapeutic Cells Immune Protection Implantable proprietary medical Human cells (donor / stem) & Technologies to protect device that provides vascularized tissues that produce & re

  5. Slide 5: Worldwide IP / Patent Portfolio

    Slide 5: Worldwide IP / Patent Portfolio

    Worldwide IP / Patent Portfolio International patents & patent applications portfolio in multiple patent families with broad application & continued expansion:  Composition & use of medical devices for delivery & cell transplantation  Glucose responsive insulin secreting stem cell technologies  L

  6. Slide 6: Sernova Pipeline

    Slide 6: Sernova Pipeline

    Sernova Pipeline CELL POUCH PRE- DEVELOPMENT CANDIDATE CLINICAL PHASE I PHASE II PHASE III STAGE INDICATION HUMAN DONOR ISLETS, P H A S E I /I I I N I T I AT E D HYPOGLYCEMIA SYSTEMIC IMMUNE DEC 2018 UNAWARENESS PROTECTION T1D A N T I C I PAT E D 2 ND ALL INSULIN LOCALLY IMMUNE- A P P R O VA L F O R

  7. Slide 7: Diabetes Market Opportunities

    Slide 7: Diabetes Market Opportunities

    Diabetes Market Opportunities IP Status 2020 Potential Patient Population Potential Commercial Opportunity (before market access considerations) T1D Severe HU T1D Severe HU Device / Method T1D Severe HU All T1D T1D Severe HU All T1D with Human with Human Patent with iPSC with iPSC with iPSC with iPS

  8. Slide 8: RM Diabetes Competitive Landscape

    Slide 8: RM Diabetes Competitive Landscape

    RM Diabetes Competitive Landscape Clinical Efficacy Data: Device Vascularization Local Immune Financial Metrics Therapeutic C-peptide Levels Islet Engraftment Protection Technology (USD Millions) Measured in Bloodstream Demonstrated in Humans Phase I/II initiated late 2018 in T1D Interim data demons

  9. Slide 9: Therapeutic Cells

    Slide 9: Therapeutic Cells

    Therapeutic Cells Therapeutic Cell Options  Human donor cells enable early safety / efficacy testing in the clinic for indications & patients with unmet needs & advanced disease (i.e. diabetes HU patients). Supply is limited; however, they enable Cell Pouch validation in preparation for stem cell t

  10. Slide 10: Immune Protection

    Slide 10: Immune Protection

    Immune Protection  Transplanted therapeutic cells must be protected from a natural immune system attack response.  While established systemic transplantation immuno-suppression (anti-rejection) drugs can be effective, local immune protection (LIP) is optimal. LIP alternatives present different opp

  11. Slide 11: Immune Protection

    Slide 11: Immune Protection

    Immune Protection Conformal Coating Technologies: • Sernova’s proprietary cellular conformal coating technology - developed and optimized with years of research • It consists of a thin biocompatible porous polymer hydrogel coating surrounding therapeutic cells (islets, stem cells) • Proven to allow

  12. Slide 12: Strategic Development Approach

    Slide 12: Strategic Development Approach

    Strategic Development Approach Device Therapeutic Immune Sernova Integrated Cells Protection RM Therapeutic Solution Immuno Portfolio Human Suppression Drugs Cell Therapeutic Donor (systemic) Pouch Cells Sernova Stem Cell Cell Encapsulation Proprietary Derived Conformal Coating Cell Pouch (iPSC / EP

  13. Slide 13: Diabetes… Hope for a Functional Cure

    Slide 13: Diabetes… Hope for a Functional Cure

    Diabetes… Hope for a Functional Cure The Reality: Diabetes is one of the most prevalent diseases & pervasive medical problems impacting society & everyday quality of life (QOL) today  463 million affected worldwide and nearly 10% of these individuals have T1D(1)  T1D represents a potential commerc

  14. Slide 14: Diabetes Clinical Progress Summary

    Slide 14: Diabetes Clinical Progress Summary

    Diabetes Clinical Progress Summary  Completion of first-in-human proof-of-concept study for diabetic condition HU  Clinical protocol & regulatory package development for US Ph I / II clinical trial for Pre 2018 diabetic HU condition (T1D Study)  FDA IND clearance to commence T1D Study  T1D Study

  15. Slide 15: Diabetes First Clinical Indication: HU

    Slide 15: Diabetes First Clinical Indication: HU

    Diabetes First Clinical Indication: HU Hypoglycemia Hypoglycemia unawareness unawareness (HU), the(HU), most the most critical critical unmet needunmet needaffects in diabetes, in diabetes, 15% of T1D affects patients 15% (~240K of T1Dinpatients patients (~240 K patients in the US alone) the US alon

  16. Slide 16: US Ph I/II Study Design

    Slide 16: US Ph I/II Study Design

    US Ph I/II Study Design US Ph I/II Safety, Tolerability, Efficacy Study Study Design: Company-sponsored IND. Open-label, single-arm study. Human donor islets are transplanted into the Cell Pouch after implantation & stable anti-rejection medication activity has been established. Primary Objective: T

  17. Slide 17: US Ph I/II Case Study Early Findings

    Slide 17: US Ph I/II Case Study Early Findings

    US Ph I/II Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study Safety Findings (90 days post-transplant) Incidence & severity of adverse events associated with Cell Pouch were monitored:  No incidences of AEs determined to be probable or highly probable to the Cell Pouch  Cel

  18. Slide 18: US Ph I/II Case Study Early Findings

    Slide 18: US Ph I/II Case Study Early Findings

    US Ph I/II Case Study Early Findings US Ph I/II Safety, Tolerability, Efficacy Study First Patient Observed Data Presented by Clinical Investigator* Early Efficacy Findings Islet Transplant Status: Before 3 Mo. After 90-day post-transplant glucose tolerance test (i.e. patient given a high sugar drin

  19. Slide 19: US Ph I/II Case Study Early Findings

    Slide 19: US Ph I/II Case Study Early Findings

    US Ph I/II Case Study Early Findings Improvement in ALL CGM Parameters Blood Glucose Over Time (mg/dL) Baseline: More excursions seen pre-transplant Parameter Baseline Post-transplant High Glucose Value (mg/dL) 285 231 Low Glucose Value (mg/dL) 50 66* # Glucose Excursions 15 3 # High Excursions 7 2

  20. Slide 20: US Ph I/II 90-Days Post Transplant

    Slide 20: US Ph I/II 90-Days Post Transplant

    US Ph I/II 90-Days Post Transplant Achievement of Secondary Endpoint “Survival of endocrine tissue in the Cell Pouch™ (defined by positive staining of islets during histological analysis) [ Time Frame: 90±5 days post-transplant for sentinel Cell Pouch™ ]” Islets Independent Pathologist reported:  a

  21. Slide 21: Earlier First-in-Human Study

    Slide 21: Earlier First-in-Human Study

    Earlier First-in-Human Study First-in-World Successful Proof-of-Concept Study Design  T1D subjects with HU & a history of severe hypoglycemic episodes  Open-label, single-arm  Donor islet transplantation 2 – 24 weeks post Cell Pouch implantation  Primary Endpoint: Safety post Cell Pouch implanta

  22. Slide 22: Hemophilia A Program

    Slide 22: Hemophilia A Program

    Hemophilia A Program Estimated  ~20 K patients across North America & EU Market  ~$10 B orphan indication Benefits of Sernova’s Cell Pouch with factor VIII releasing cells:  Patients receive regular infusions of missing Standard clotting factors (i.e. factor VIII)  Reduce / eliminate factor of C

  23. Slide 23: Thyroid Disease Program

    Slide 23: Thyroid Disease Program

    Thyroid Disease Program Estimated  150,000 thyroidectomies performed annually in US  ~$2.2 B market opportunity Market Benefits of Sernova’s Cell Pouch with Thyroid releasing cells:  Patients require lifelong thyroid hormone  Reduce / eliminate daily life replacement therapy Standard long thyroi

  24. Slide 24: NEXT STEPS – Action Plan

    Slide 24: NEXT STEPS – Action Plan

    NEXT STEPS – Action Plan  Develop licensed/acquired local immune-protection technologies for Platform therapeutic cells Technology  Advance local immune-protected diabetes stem cell technology in preparation for First-in-Man (FIM) study  Expand existing strong worldwide multi-family patent portfo

  25. Slide 25: Management Team

    Slide 25: Management Team

    Management Team Dr. Philip Toleikis PRESIDENT & CEO  20+ years experience in biotech management & product development in pharmaceutical & combination products.  Previous Angiotech VP R&D (achieved $2 B market cap; product revenue $200 M per year). David Swetlow CPA, CA Board of Directors CFO  Fra

  26. Slide 26: 700 Collip Circle, Suite 114 London, Ontario Canada

    Slide 26: 700 Collip Circle, Suite 114 London, Ontario Canada

    700 Collip Circle, Suite 114 London, Ontario Canada N6G 4X8 info@sernova.com www.sernova.com

Source: Internet Archive copy of sernova.com

More decks from Sernova Biotherapeutics Inc

All 29 Sernova Biotherapeutics decks